Jacobs selected for Pfizer's Swedish biotech project
Jacobs Engineering Group has been selected to develop a concept and preliminary design for a new biotech pharmaceutical facility for Pfizer's Strangnas manufacturing centre in Sweden.
Jacobs Engineering Group has been selected to develop a concept and preliminary design for a new biotech pharmaceutical facility for Pfizer's Strangnas manufacturing centre in Sweden.
The value of the contract, which will be executed from Jacobs' office in Reading in the UK, has not been disclosed.
The new facility enables Pfizer to ensure manufacturing capacity for existing biotech-derived pharmaceutical products. Jacobs is designing the manufacturing facility in accordance with current Good Manufacturing Practices (cGMP), Pfizer quality standards, and US FDA and the European Medicines Agency licensing requirements for bulk API (active pharmaceutical ingredient) production.
'We are excited to become part of Pfizer's biotech initiative,' said Jacobs Group vice president Phil Stassi. 'This award combines the product technology strengths of Pfizer with the global biotech project delivery expertise of Jacobs.'
